Compound interferon inducing agent lozenge

A technology of interferon and buccal tablets, applied in the field of medical bioengineering, can solve the problems of complex production process, limited source, large side effects, etc., and achieve the effect of mature process and convenient source

Inactive Publication Date: 2006-06-28
钱汶光
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Exogenous interferon, the production process is complicated, the source is limited, the cost is high, the price is expensive, the side effect is large, and the use is inconvenient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0170] A kind of compound interferon-inducing agent buccal tablet of the present invention is dosed according to Table 4-5. Proceed as follows:

[0171] 1. Take sterile live attenuated Newcastle disease virus vaccine, astragalus root, glycyrrhizin, and stabilizer, mix them in a sterile stainless steel tray, and freeze them into the main drug freeze-dried powder with a freeze dryer.

[0172] 2. Take each auxiliary material, first dry bake in an oven at 100-105°C for 1 hour to sterilize, then take dextrin, lactose, magnesium stearate, mix them evenly, then mix them evenly with starch, and pass through a 80-100 mesh sieve The mixed auxiliary material soft material is prepared, and then the auxiliary soft material is passed through a 12-16 mesh sieve and dried in an oven at 60° C. for 4-6 hours to obtain blank granules with a moisture content lower than 5%.

[0173] 3. Fully mix the lyophilized powder of the main drug with the same amount of blank granules, and then fully mix the...

Embodiment 2

[0176] A kind of compound interferon-inducing agent buccal tablet of the present invention is dosed according to Table 4-5. Proceed as follows:

[0177] 1. First inactivate the sterile Newcastle disease virus into a dead virus, and then carry out ultrafiltration and concentration. Then take astragalus, glycyrrhizin, and stabilizer, put them in a sterile stainless steel plate, mix well and evenly to form the main medicine mixture.

[0178] 2. Take each auxiliary material, first dry bake in an oven at 100-105°C for 1 hour to sterilize, then take dextrin, lactose, magnesium stearate, mix them evenly, then mix them evenly with starch, and pass through a 80-100 mesh sieve The mixed auxiliary material soft material is prepared, and then the auxiliary soft material is passed through a 12-16 mesh sieve and dried in an oven at 60° C. for 4-6 hours to obtain blank granules with a moisture content lower than 5%.

[0179] 3. Fully mix the main drug mixture with the same amount of blank ...

Embodiment 3

[0182] A kind of compound interferon-inducing agent buccal tablet of the present invention is dosed according to Table 4-5. Prepared according to the usual large-scale tablet production method, the steps are as follows:

[0183] 1. Main drug treatment: first take the sterile Newcastle disease virus attenuated and inactivated vaccine or inactivated dead vaccine, carry out ultrafiltration and concentration treatment, and use it for later use after passing the sterility test.

[0184] 2. Treatment of excipients and stabilizers: dry-bake the excipients and stabilizers at 100-105°C for 1 hour, and pass the sterility test for later use.

[0185] 3. Preparation of blank granules: Take the excipients and stabilizers treated in step 2. After fully mixing in the mixer, pass through a 100-mesh sieve for 3 times, add 40% ethanol, stir into a soft material, pass through a 14-mesh sieve, and pass through a 56°C Bake for 4-5 hours to make blank granules.

[0186] 4. Preparation of interfer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention is compound interferon inducing agent lozenge, relates to biomedicine engineering, and aims at providing lozenge capable of inducing body to generate endogenous interferon and with high curative effect, less side effect, small dosage and wide application. Each of the compound interferon inducing agent lozenge contains attenuated Newcastle disease virus vaccine or deactivated Newcastle disease virus vaccine 10-120 hemagglutination units, astragalus root 1-2000 mg, liquiritigenin 1-1000 mg, supplementary material and stabilizer. The compound interferon inducing agent lozenge is suitable for preventing SARS and other viral infectious respiratory tract diseases, and has also auxiliary treatment effect on various kinds of tumor, hepatitis B and hepatitis C.

Description

technical field [0001] The invention relates to the technical field of medical bioengineering. Especially endogenous interferon inducer in cell bioengineering. Background technique [0002] The interferon system is a ubiquitous system in living organisms. It is a defensive substance produced by the body itself to resist the invasion of foreign viruses and maintain the self-stabilization of the body or cells. Inhibiting virus replication and reproduction is one of the most basic and common properties of interferon, which is effective for almost all human pathogenic viruses. In the process of virus infection, the production of interferon is a common phenomenon, and the interferon produced by a virus infection can produce resistance to many viruses. [0003] Because interferon has multiple biological effects such as broad-spectrum antiviral and immune regulatory responses, more than 40 countries have approved the use of interferon preparations to treat more than 30 diseases, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/17A61K9/20A61P31/12
Inventor 钱汶光
Owner 钱汶光
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap